Mixidine is negative chronotropic agent patented by McNeil Laboratories. Mixidine produced a dose-related decrease in heart rate elevated reflexly by aminophylline, by beta-adrenergic stimulation induced by isoproterenol, by sympathetic nerve stimulation and by intravenous infusion of glucagon. Mixidineattenuated the increase in contractile force produced by sympathetic nerve stimulation but not that induced by isoproterenol. The compound antagonized the increase in the rate of isolated guinea-pig atria induced by both isoproterenol and histamine. In the conscious dog, Mixidine caused no decrease in resting heart rate, mean arterial pressure and cardiac output. It reduced atropine-induced sinus tachycardia as well as that induced by treadmill exercise.

Metipirox was developed as a bactericide agent. Information about the current use of this compound is not available

Myfadol is a phenacylpiperidine derivative patented by Tanabe Seiyaku Co., Ltd as low molecular weight non-peptide analgesic. Myfadol produces hot-plate analgesia in rodents with minimal side-effects, and when given parenterally in humans produces analgesia to experimentally-produced and postoperative pain.

Perfomedil is a vasodilator. Perfomedil is a buflomedil analog. Perfomedil like its parent compound buflomedil, antagonizes both alpha1- and alpha2-adrenoceptors. An important difference between perfomedil and its parent compound is the preferential antagonism exerted against alpha2-adrenoceptors. In the saphenous vein of the dog perfomedil acts as a relatively weak alpha-adrenergic blocker in vascular smooth muscle, with a preferential effect on postjunctional alpha2-adrenoceptors. At the adrenergic nerves, the compounds inhibit prejunctional alpha2-adrenoceptors and displace stored transmitter.

Remiprostol (also known as SC-46275) is a potent, long-acting gastric antisecretory agent that is not readily available systemically after oral administration. This prostaglandin analog is a very potent and highly selective EP3 receptor agonist with antisecretory and cytoprotective actions. Remiprostol was suggested to be potentially useful in the therapeutic treatment of inflammatory diseases such as peptic ulcer disease (painful sores or ulcers in the stomach or small intestine), ulcerative colitis, Crohn's disease, and autoimmune inflammatory diseases of the central nervous system.

Hexaprofen, a potent anti-inflammatory agent, is an inhibitor of platelet aggregation. Experiments on mice have shown that hexaprofen could reduce the quantity and size of Lewis lung carcinoma (LLC) tumor nodules.